Estimating the potential effects of a vaccine program against an emerging influenza pandemic - United States

Clinical Infectious Diseases

Volumn 60, Issue , 2015, Pages S20-S29

  Biggerstaff, Matthew ^a   Reed, Carrie ^a   Swerdlow, David L ^b   Gambhir, Manoj ^b,c   Graitcer, Samuel ^d   Finelli, Lyn ^a   Borse, Rebekah H ^e   Rasmussen, Sonja A ^f   Meltzer, Martin I ^e   Bridges, Carolyn B ^d  

^a Influenza Division   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c MONASH UNIVERSITY   (Australia)

^d Immunization Services Division NCIRD   (United States)

^e NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^f NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Influenza; influenza A(H7N9); influenza vaccine; mathematical modeling; pandemic

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG EFFICACY; EPIDEMIC; FATALITY; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INFANT; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N9; NEWBORN; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; UNITED STATES; AGED; INFLUENZA A VIRUS (H7N9); MAJOR CLINICAL STUDY; COMMUNICABLE DISEASES, EMERGING; DISASTER PLANNING; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; INFLUENZA, HUMAN; ORGANIZATION AND MANAGEMENT; PANDEMICS; PREVENTIVE HEALTH SERVICE; PROCEDURES; THEORETICAL MODEL;

COMMUNICABLE DISEASES, EMERGING; DISASTER PLANNING; EPIDEMIOLOGICAL MONITORING; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, THEORETICAL; PANDEMICS; UNITED STATES;

EID: 84928978255     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1175     Document Type: Article

References (30)

1. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med 2000; 51:407-21.
2. Jhung MA, Swerdlow D, Olsen SJ, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis 2011; 52(suppl 1):S13-26.
3. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97.
4. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85.
5. World Health Organization. Human infection with avian influenza A (H7N9) virus-update. Available at: http://www.who.int/csr/don/2013-08-11/en/index.html. Accessed 19 August 2013.
6. Xiong X, Martin SR, Haire LF, et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013; 499:496-9.
7. Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013; 499:500-3.
8. Boni MF, Chau NV, Dong N, et al. Population-level antibody estimates to novel influenza A/H7N9. J Infect Dis 2013; 208:554-8.
9. Centers for Disease Control and Prevention. Emergence of avian influenza A(H7N9) virus causing severe human illness-China, February- April 2013. MMWR Morb Mortal Wkly Rep 2013; 62:366-71.
10. Borse RH, Shrestha SS, Fiore AE, et al. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009- 2010. Emerg Infect Dis 2013; 19:439-48.
11. Meltzer MI, Gambhir M, Atkins CY, Swerdlow DL. Standardizing scenarios to assess the need to respond to an influenza pandemic. Clin Infect Dis 2015; 60(suppl 1):S1-8.
12. Reed C, Biggerstaff M, Finelli L, et al. Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics. Emerg Infect Dis 2013; 19:85-91.
13. Veguilla V, Hancock K, Schiffer J, et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011; 49:2210-5.
14. Centers for Disease Control and Prevention. FluVaxView influenza vaccinationcoverage. Available at: http://www.cdc.gov/flu/fluvaxview/interactive.htm. Accessed 16 September 2013.
15. Sambhara S, Poland GA. H5N1 avian influenza: preventive and therapeutic strategies against a pandemic. Annu Rev Med 2010; 61:187-98.
16. Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012; 7:e49704.
17. Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97.
18. Centers for Disease Control and Prevention. Influenza vaccination coverage:how well did we do in 2012-13. Available at: http://www.cdc.gov/flu/fluvaxview/1213season.htm. Accessed 2 August 2013.
19. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80.
20. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine 2010; 28:7460-7.
21. Centers for Disease Control and Prevention. Final estimates for 2009- 10 seasonal influenza and influenza A (H1N1) 2009 monovalent vaccination coverage-United States, August 2009 through May, 2010. Available at: http://www.cdc.gov/flu/fluvaxview/coverage-0910estimates.htm. Accessed 20 August 2013.
22. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733-9.
23. Lopez-Macias C. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother 2012; 8:411-4.
24. Goad JA, Taitel MS, Fensterheim LE, Cannon AE. Vaccinations administered during off-clinic hours at a national community pharmacy: implications for increasing patient access and convenience. Ann Fam Med 2013; 11:429-36.
25. Interfaith Health Program. Public health and faith community partnerships: model practices to increase influenza prevention among hard to reach populations. Available at: http://ihpemory.org/ihp-programs/public-health-and-faith-community-partnerships/. Accessed 5 February 2014.
26. US Department of Health and Human Services. News release: HHS boosts national capacity to produce pandemic flu vaccine. Available at: http://www.phe.gov/Preparedness/news/Pages/fill-finish-130930.aspx. Accessed 18 February 2014.
27. Brammer L, Blanton L, Epperson S, et al. Surveillance for influenza during the 2009 influenza A (H1N1) pandemic-United States, April 2009- March 2010. Clin Infect Dis 2011; 52(suppl 1):S27-35.
28. President's Council of Advisors on Science and Technology. Report to the President on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza. Available at: http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf. Accessed 19 September2013.
29. De Groot AS, Ardito M, Terry F, et al. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccin Immunother 2013; 9:950-6.
30. Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013; 369:2564-6.